查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088844

人類胚胎幹細胞市場：依產品、適應症、技術、應用和最終用戶分類－2026-2032年全球市場預測

Human Embryonic Stem Cells Market by Product, Indication, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類胚胎幹細胞市場規模將達到 53.5 億美元，複合年成長率為 11.03%。

主要市場統計數據
基準年 2025 25.7億美元
預計年份：2026年 28.3億美元
預測年份 2032 53.5億美元
複合年成長率 (%) 11.03%

人類胚胎幹細胞（hESCs）是一種來自於胚囊內細胞團的多功能細胞，在再生醫學、發育生物學、藥物研發、疾病建模和毒性篩檢等領域持續發揮核心作用。自1998年首次成功建立人類胚胎幹細胞株係以來，hESC平台已幫助研究人員研究人類早期發育，並生成了多種分化細胞，例如心肌細胞、視網膜色素上皮細胞、前驅細胞、神經細胞和肝細胞樣細胞。

人類胚胎幹細胞市場的發展受到高品質多功能細胞模型、可重複的細胞分化方案、符合GMP標準的細胞生產以及細胞治療轉化研究的需求所驅動。異質性無成分培養系統、單細胞分析、基因組編輯、類器官平台和自動化品管等方面的進步也推動了市場成長。同時，倫理審查、捐贈者知情同意、胚胎使用相關法規以及跨境政策差異仍然是商業策略和研究中需要考慮的關鍵因素。

人類胚胎幹細胞（hESCs）領域的變革性變化

人類胚胎幹細胞（hESCs）領域正從探索性學術研究轉向更標準化、轉化應用和品管的平台。研究機構和生產商正優先考慮無飼養細胞和無異質成分的培養基、預定義的細胞外基質、經過驗證的分化工作流程以及支持可重複性、細胞身份驗證、無菌保證、基因組穩定性和法規遵從性的放行檢驗標準。

人工智慧（AI）的累積影響

人工智慧（AI）正成為人類胚胎幹細胞（hESC）研究的強大驅動力。 AI驅動的影像分析有助於進行集落形態評估、多功能監測、污染檢測和分化階段分類。機器學習也被應用於單細胞RNA定序、蛋白質體學、表觀基因以及高內涵成像資料的解讀，幫助研究人員識別分化路徑並最佳化分化條件。

主要區域趨勢

亞太地區是人類胚胎幹細胞領域一個極為活躍的區域，日本、中國、韓國、印度、澳洲和東南亞國協在大力投資再生醫學、幹細胞庫、細胞治療基礎設施、精準醫療和生物製造能力。日本因其在再生醫學政策和多功能細胞科學方面的創新而備受讚譽，而中國正在拓展其轉化研究和臨床基礎設施。韓國在細胞治療和生物製程能力方面表現出色，印度則在加強品管。澳洲也透過其高品質的生物醫學研究網路做出了貢獻。

關鍵小組洞察

在東協地區，新加坡是生物醫學研究、GMP生產和轉化科學的區域中心；泰國、馬來西亞、印尼、越南和菲律賓正在建立臨床研究能力和醫療創新生態系統。海灣合作理事會（GCC）國家正在加大對生命科學、精準醫療、基因組學和醫院創新領域的投資，為幹細胞研究夥伴關係和未來先進治療基礎設施的建設創造了機會。

主要國家的概況

美國憑藉其頂尖大學、美國國立衛生研究院 (NIH) 的完善體係以及美國食品藥物管理局 (FDA) 對細胞和基因療法的監管，在人類胚胎幹細胞 (hESC) 相關研究成果、生物技術公司建立、創業融資和臨床應用基礎設施方面處於主導地位。加拿大以其再生醫學網路和強大的轉化醫學合作而聞名，而墨西哥則透過學術醫學、民用醫學和跨境研究機會來提升自身能力。巴西憑藉其一流的研究型大學和重要的公共衛生地位，是拉丁美洲幹細胞科學領域最重要的市場。

為行業領導者提供的實用建議

產業領導者應優先考慮來源符合倫理規範且特徵明確的人類胚胎幹細胞 (hESC) 株系。這需要提供捐贈者知情同意書、可追溯性、核型穩定性、多功能標記、無菌檢測、黴漿菌檢測和病原體篩檢等文件。投資於異質性、無飼養層細胞且符合 GMP 標準的流程可以降低轉化風險，並提高夥伴關係、許可、技術轉移和監管申報的準備程度。

調查方法

本執行摘要採用系統的二手研究方法編寫，重點關注公開可查且檢驗的資訊來源，包括監管指南、同行評審的科學文獻、臨床試驗註冊資訊、機構幹細胞資源、政府資助資訊以及國際生物技術政策研究途徑。本摘要強調基於證據的解讀，而非未經證實的市場規模估算、市佔率計算或預測。

結論

人類胚胎幹細胞在再生醫學、疾病建模、發育生物學和高價值藥物研發中繼續發揮基礎性作用。它們能夠產生特定的人類細胞類型，這使得該領域具有長期的重要性，尤其是在細胞療法、類器官系統、微生理模型和精準毒理學日益成為生物醫學創新核心的情況下。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 人類胚胎幹細胞市場：依產品分類

  • 配件和耗材
    • 配件
    • 消耗品
  • 分化誘導試劑
    • 生長因子試劑盒
    • 低分子量試劑
  • 人類胚胎幹細胞培養基
    • 血清基質
    • 無血清
  • 人類胚胎幹細胞株
    • 臨床等級
    • 研究級
  • 血清和生長因子
    • 生長因子
    • 血清

第8章 人類胚胎幹細胞市場：依適應症分類

  • 心血管疾病
    • 心臟衰竭
    • 缺血性心臟疾病
  • 糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 神經病變
    • 阿茲海默症
    • 帕金森氏症
  • 整形外科疾病
    • 骨再生
    • 軟骨修復

第9章 人類胚胎幹細胞市場：依技術分類

  • 同種異體人類胚胎幹細胞（HESCs）
  • 自體胚胎幹細胞（HESCs）

第10章 人類胚胎幹細胞市場：依應用領域分類

  • 基礎研究
  • 臨床研究
  • 藥物發現與開發
    • 針對性篩檢
    • 毒性篩檢
  • 再生醫學
    • 細胞療法
    • 組織工程
  • 毒性測試

第11章 人類胚胎幹細胞市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 醫院和診所
  • 製藥和生物技術公司
    • 生技公司
    • 製藥公司

第12章 人類胚胎幹細胞市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 人類胚胎幹細胞市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 人類胚胎幹細胞市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Astellas Pharma Inc.
  • ATCC
  • BD Biosciences
  • Bio-Techne Corporation
  • BlueRock Therapeutics, Inc.
  • Cell Engineering Corporation
  • Cellartis AB
  • Corning Incorporated
  • Cynata Therapeutics Limited
  • GE Healthcare Life Sciences
  • Lineage Cell Therapeutics, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Organovo Holdings, Inc.
  • PeproTech, Inc.
  • Pluri Inc.
  • PromoCell GmbH
  • R&D Systems, Inc.
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.
Product Code: MRR-AD36CD897E4B

The Human Embryonic Stem Cells Market is projected to grow by USD 5.35 billion at a CAGR of 11.03% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.57 billion
Estimated Year [2026] USD 2.83 billion
Forecast Year [2032] USD 5.35 billion
CAGR (%) 11.03%

Human embryonic stem cells (hESCs) are pluripotent cells derived from the inner cell mass of the blastocyst and remain central to regenerative medicine, developmental biology, drug discovery, disease modeling, and toxicology screening. Since the first successful derivation of human embryonic stem cell lines in 1998, hESC platforms have helped researchers study early human development and generate differentiated cell types, including cardiomyocytes, retinal pigment epithelial cells, pancreatic progenitors, neurons, and hepatocyte-like cells.

The human embryonic stem cells market is shaped by demand for high-quality pluripotent stem cell models, reproducible cell differentiation protocols, GMP-grade cell manufacturing, and translational research in cell therapy. Growth is also supported by advances in xeno-free culture systems, single-cell analysis, genome editing, organoid platforms, and automated quality control. At the same time, ethical review, donor consent, embryo-use regulations, and cross-border variability in policy remain defining considerations for commercial strategy and research adoption.

Transformative Shifts in the hESC Landscape

The hESC landscape is shifting from exploratory academic research toward more standardized, translational, and quality-controlled platforms. Laboratories and manufacturers are prioritizing feeder-free and xeno-free media, defined extracellular matrices, validated differentiation workflows, and release-testing standards that support reproducibility, cell identity confirmation, sterility assurance, genomic stability, and regulatory readiness.

Another major transformation is the movement from two-dimensional culture toward organoids, assembloids, microphysiological systems, and high-content screening. These systems improve physiological relevance for drug discovery and disease modeling while reducing dependence on animal models. Strategic collaborations among universities, biotechnology developers, contract development and manufacturing organizations, and hospital-based translational centers are accelerating the path from pluripotent stem cell biology to clinical-grade applications.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator for human embryonic stem cell research. AI-enabled image analysis supports colony morphology assessment, pluripotency monitoring, contamination detection, and differentiation-stage classification. Machine learning is also being used to interpret single-cell RNA sequencing, proteomics, epigenomics, and high-content imaging data, helping researchers identify lineage trajectories and optimize differentiation conditions.

The cumulative impact is greater process control across research and manufacturing. AI can reduce manual variability, improve batch comparability, predict culture failures earlier, and support more efficient experimental design. For hESC-derived therapeutics, AI-driven analytics can strengthen potency assays, cell identity verification, and safety screening, although all AI outputs still require biological validation, data governance, and alignment with regulatory expectations for explainability, auditability, and traceability.

Key Regional Insights

Asia-Pacific is a highly dynamic region for human embryonic stem cells, with Japan, China, South Korea, India, Australia, and ASEAN economies investing in regenerative medicine, stem cell banking, cell therapy infrastructure, precision medicine, and biomanufacturing capabilities. Japan is recognized for regenerative medicine policy innovation and pluripotent stem cell science, China is expanding translational research and clinical infrastructure, South Korea has strong cell therapy and bioprocessing capabilities, India is strengthening quality oversight, and Australia contributes through high-quality biomedical research networks.

North America remains a leading region for hESC research due to its concentration of biomedical universities, NIH-supported research infrastructure, private biotechnology investment, and clinical trial networks. The United States drives much of the region's translational activity through established regulatory oversight for cell and gene therapies, while Canada contributes through regenerative medicine networks, ethics governance, and collaborative research programs. Latin America is emerging through Brazil and Mexico, where academic research, public health priorities, and healthcare modernization are expanding opportunities, although infrastructure depth and regulatory maturity vary across countries.

Europe is supported by advanced academic centers, the European Medicines Agency's advanced therapy medicinal product framework, and country-specific approaches to embryo research. Germany, France, Italy, Spain, and the United Kingdom maintain strong biomedical ecosystems, though legal permissions, funding conditions, and ethical review processes differ by jurisdiction. The Middle East is investing in advanced healthcare hubs, genomics, and biomanufacturing, particularly in GCC states, while Africa remains earlier-stage for hESC commercialization, with research partnerships, academic capacity building, and interest in affordable regenerative medicine platforms gradually increasing regional relevance.

Key Group Insights

Within ASEAN, Singapore is a regional anchor for biomedical research, GMP manufacturing, and translational science, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are building clinical research capacity and healthcare innovation ecosystems. The GCC is increasing investment in life sciences, precision medicine, genomics, and hospital-based innovation, creating opportunities for stem cell research partnerships and future advanced therapy infrastructure.

The European Union offers a structured regulatory pathway for advanced therapy medicinal products and strong research funding mechanisms, but hESC rules are not fully uniform across member states, making country-level compliance essential. BRICS economies combine large patient populations, expanding biotechnology sectors, and rising government support for advanced medical research, with China, India, and Brazil particularly active in regenerative medicine, cell biology, and translational research capacity building.

G7 countries represent the most mature concentration of biomedical funding, intellectual property generation, regulatory expertise, clinical translation capacity, and advanced therapy manufacturing infrastructure. NATO member countries overlap heavily with North American and European innovation hubs, where defense-related biomedical research, trauma medicine, tissue repair, radiation injury research, and biomanufacturing resilience can support broader stem cell technology development.

Key Country Insights

The United States leads in hESC-related research output, biotechnology formation, venture funding, and clinical translation infrastructure, supported by major universities, the NIH ecosystem, and established FDA oversight for cell and gene therapies. Canada is known for regenerative medicine networks and strong translational collaboration, while Mexico is developing capabilities through academic medicine, private healthcare, and cross-border research opportunities. Brazil is Latin America's most visible market for stem cell science, supported by major research universities and public health relevance.

The United Kingdom remains influential through stem cell governance, life sciences clusters, and clinical trial capacity. Germany, France, Italy, and Spain contribute strong biomedical research, cell therapy expertise, and advanced therapy manufacturing capabilities, with country-specific ethical and legal frameworks shaping hESC activity. Russia maintains scientific capacity in cell biology and regenerative medicine research, although international collaboration conditions, funding access, and regulatory alignment influence market participation.

China is rapidly expanding stem cell research, biomanufacturing, and translational medicine, while India combines a large scientific talent base, cost-effective research capacity, and growing regulatory attention to cell therapy quality. Japan is globally recognized for regenerative medicine policy innovation and pluripotent stem cell science, Australia contributes through high-quality biomedical research and clinical networks, and South Korea remains a strong hub for cell therapy, bioprocessing, and life sciences manufacturing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize ethically sourced, well-characterized hESC lines with documented donor consent, traceability, karyotype stability, pluripotency markers, sterility testing, mycoplasma testing, and pathogen screening. Investment in xeno-free, feeder-free, and GMP-compatible workflows can reduce translational risk and improve readiness for partnerships, licensing, technology transfer, and regulatory submissions.

Organizations should integrate AI-enabled quality analytics, single-cell multi-omics, automated imaging, digital batch records, and validated data governance early in development. Strategic collaborations with academic centers, CDMOs, hospital networks, ethics committees, and regulatory experts can accelerate differentiation protocol validation, potency assay design, comparability studies, and clinical trial planning. Leaders should also monitor country-specific embryo research laws, patentability rules, biobanking requirements, and import-export controls to avoid delays in global commercialization.

Research Methodology

This executive summary is developed using a structured secondary-research approach focused on publicly available and verifiable sources, including regulatory agency guidance, peer-reviewed scientific literature, clinical trial registries, institutional stem cell resources, government funding information, and international biotechnology policy references. Emphasis is placed on evidence-based interpretation rather than unsupported market sizing, market share calculation, or forecasting.

The methodology evaluates scientific maturity, regulatory environment, ethical governance, translational readiness, manufacturing infrastructure, regional investment patterns, and adoption of enabling technologies such as AI, organoids, CRISPR-based research tools, and single-cell analytics. Insights are triangulated across multiple source categories to support reliable market analysis for the human embryonic stem cells industry.

Conclusion

Human embryonic stem cells continue to play a foundational role in regenerative medicine, disease modeling, developmental biology, and high-value drug discovery. Their ability to generate specialized human cell types gives the field long-term relevance, particularly as cell therapy, organoid systems, microphysiological models, and precision toxicology become more central to biomedical innovation.

The market's next phase will be defined by ethical governance, regulatory clarity, automated quality control, AI-enabled analytics, and scalable GMP manufacturing. Organizations that combine scientific rigor with transparent compliance, validated data systems, and strong regional strategy will be best positioned to capture opportunities in the evolving human embryonic stem cells market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Embryonic Stem Cells Market, by Product

  • 7.1. Accessories And Consumables
    • 7.1.1. Accessories
    • 7.1.2. Consumables
  • 7.2. Differentiation Reagents
    • 7.2.1. Growth Factor Kits
    • 7.2.2. Small Molecule Reagents
  • 7.3. Human Embryonic Stem Cell Culture Media
    • 7.3.1. Serum Based
    • 7.3.2. Serum Free
  • 7.4. Human Embryonic Stem Cell Lines
    • 7.4.1. Clinical Grade
    • 7.4.2. Research Grade
  • 7.5. Serums And Growth Factors
    • 7.5.1. Growth Factors
    • 7.5.2. Serum

8. Human Embryonic Stem Cells Market, by Indication

  • 8.1. Cardiovascular Disorders
    • 8.1.1. Heart Failure
    • 8.1.2. Ischemic Heart Disease
  • 8.2. Diabetes
    • 8.2.1. Type 1 Diabetes
    • 8.2.2. Type 2 Diabetes
  • 8.3. Neurological Disorders
    • 8.3.1. Alzheimers Disease
    • 8.3.2. Parkinsons Disease
  • 8.4. Orthopedic Disorders
    • 8.4.1. Bone Regeneration
    • 8.4.2. Cartilage Repair

9. Human Embryonic Stem Cells Market, by Technology

  • 9.1. Allogeneic Hesc
  • 9.2. Autologous Hesc

10. Human Embryonic Stem Cells Market, by Application

  • 10.1. Basic Research
  • 10.2. Clinical Research
  • 10.3. Drug Discovery And Development
    • 10.3.1. Target Screening
    • 10.3.2. Toxicity Screening
  • 10.4. Regenerative Medicine
    • 10.4.1. Cell Therapy
    • 10.4.2. Tissue Engineering
  • 10.5. Toxicology Testing

11. Human Embryonic Stem Cells Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals And Clinics
  • 11.4. Pharmaceutical And Biotechnology Companies
    • 11.4.1. Biotechnology Companies
    • 11.4.2. Pharmaceutical Companies

12. Human Embryonic Stem Cells Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Human Embryonic Stem Cells Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Embryonic Stem Cells Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Astellas Pharma Inc.
  • 16.2. ATCC
  • 16.3. BD Biosciences
  • 16.4. Bio-Techne Corporation
  • 16.5. BlueRock Therapeutics, Inc.
  • 16.6. Cell Engineering Corporation
  • 16.7. Cellartis AB
  • 16.8. Corning Incorporated
  • 16.9. Cynata Therapeutics Limited
  • 16.10. GE Healthcare Life Sciences
  • 16.11. Lineage Cell Therapeutics, Inc.
  • 16.12. Lonza Group Ltd.
  • 16.13. Merck KGaA
  • 16.14. Miltenyi Biotec GmbH
  • 16.15. Organovo Holdings, Inc.
  • 16.16. PeproTech, Inc.
  • 16.17. Pluri Inc.
  • 16.18. PromoCell GmbH
  • 16.19. R&D Systems, Inc.
  • 16.20. STEMCELL Technologies Inc.
  • 16.21. Takara Bio Inc.
  • 16.22. Thermo Fisher Scientific, Inc.
  • 16.23. ViaCyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACCESSORIES AND CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACCESSORIES AND CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACCESSORIES AND CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACCESSORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACCESSORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACCESSORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIFFERENTIATION REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIFFERENTIATION REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIFFERENTIATION REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GROWTH FACTOR KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GROWTH FACTOR KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GROWTH FACTOR KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULE REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULE REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULE REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN EMBRYONIC STEM CELL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN EMBRYONIC STEM CELL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN EMBRYONIC STEM CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SERUM BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SERUM BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SERUM BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SERUM FREE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SERUM FREE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SERUM FREE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN EMBRYONIC STEM CELL LINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN EMBRYONIC STEM CELL LINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN EMBRYONIC STEM CELL LINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL GRADE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL GRADE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL GRADE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RESEARCH GRADE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESEARCH GRADE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RESEARCH GRADE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SERUMS AND GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SERUMS AND GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SERUMS AND GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALZHEIMERS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALZHEIMERS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALZHEIMERS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARKINSONS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARKINSONS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARKINSONS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORTHOPEDIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORTHOPEDIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORTHOPEDIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BONE REGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BONE REGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BONE REGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC HESC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC HESC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC HESC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOLOGOUS HESC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOLOGOUS HESC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOLOGOUS HESC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CLINICAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CLINICAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TARGET SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGET SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TARGET SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TOXICITY SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TOXICITY SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TOXICITY SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 267. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 269. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 271. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 272. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 276. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 277. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 278. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 282. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 283. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. GCC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 321. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 323. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 324. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 325. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2018-2032 (USD MILLION)
  • TABLE 326. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 327. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 328. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 330. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)

T